|
Arecor has adopted a flexible approach to accommodate the requirements of their partners developing biopharmaceuticals, medical devices or diagnostics. Once a feasibility study is concluded or near completion, Arecor's partners are encouraged to consider the next stage in product development. Through a series of discussions Arecor is able to tailor a customised approach for each partner under a research or collaborative agreement. A research agreement allows partners access to proprietary information for them to continue development within their own facilities and to draw upon Arecor’s advice and support when necessary. A collaborative agreement provides Arecor’s partners access to ongoing assistance with the management of product development.
A Research or Collaborative agreement allows a partner to continue the development of their product but it does not permit them to commercialise the product or publish / patent the results without the prior approval of Arecor.
|
|
|
ArestatTM comprises two fundamentally different aspects of our platform stabilization technology. Both utilize excipients and buffers approved by the FDA and EMEA in an unconventional manner to achieve the desired stability
Both platform technologies are available for licensing for applications involving therapeutic proteins, vaccines, medical devices and diagnostics
|
